Application

Anti-Early Endosomal Antigen 1 (N-terminal) antibody produced in rabbit has been used in immunoblotting and immunofluorescence.

Biochem/physiol Actions

Early Endosomal Antigen 1 (EEA1) localization in endosomes is implicated in subacute systemic lupus erythematosus. Endosomal targeting of EEA1 also requires its binding to the active form of the small GTPase Rab5. The binding of EEA1 to phosphatidylinositol 3 phosphate (PtdInsP) and rabaptin-5 (Rab5)-GTP is essential for the localization and function of EEA1 in endocytic membrane fusion. Anti-EEA1 may be used as an early endosome marker.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

The gene Early Endosome Antigen 1 (EEA1) encodes for around 1400 amino acid proteins. It is a peripheral membrane protein associated with the cytoplasmic face of early endosomes. It is a 162 kDa autoantigen protein. EEA1 is a dimer, which comprises extensive coiled-coil regions. At its C-terminus, it contains a cysteine-rich zinc-finger-like domain named FYVE domain. This FYVE domain is conserved from yeast to man. FYVE domain is implicated in the specific localization of EEA1 to endosomes.

Immunogen

synthetic peptide corresponding amino acid residues 24-40 of human EEA1 with C-terminal added cysteine, conjugated to KLH. The corresponding sequence is identical in mouse.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.